LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Ligand Pharmaceuticals Inc

Closed

SectorHealthcare

194.64 -3.63

Overview

Share price change

24h

Current

Min

193.84

Max

199.02

Key metrics

By Trading Economics

Income

-72M

45M

Sales

-56M

60M

P/E

Sector Avg

32.685

57.05

Profit margin

75.058

Employees

47

EBITDA

-83M

66M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+22.81% upside

Dividends

By Dow Jones

Next Earnings

7 maj 2026

Market Stats

By TradingEconomics

Market Cap

381M

4B

Previous open

198.27

Previous close

194.64

News Sentiment

By Acuity

50%

50%

158 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 mar 2026, 17:33 UTC

Major News Events

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Major News Events

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Major News Events

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mar 2026, 14:50 UTC

Major Market Movers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mar 2026, 14:37 UTC

Acquisitions, Mergers, Takeovers

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mar 2026, 14:29 UTC

Major News Events

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 mar 2026, 14:16 UTC

Major News Events

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Market Talk
Major News Events

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Market Talk
Major News Events

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Market Talk
Major News Events

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Major News Events

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Market Talk
Major News Events

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Market Talk
Major News Events

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mar 2026, 15:00 UTC

Major News Events

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mar 2026, 14:36 UTC

Market Talk
Major News Events

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mar 2026, 14:26 UTC

Market Talk
Major News Events

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 mar 2026, 14:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 14:14 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Ligand Pharmaceuticals Inc Forecast

Price Target

By TipRanks

22.81% upside

12 Months Forecast

Average 250.17 USD  22.81%

High 277 USD

Low 230 USD

Based on 7 Wall Street analysts offering 12 month price targets forLigand Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

102.5 / 109.24Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

158 / 349 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat